Neither the PPAR agonists Livdelzi® (seladelpar) and Iqirvo® (elafibranor)—which have been conditionally approved for second-line use in PBC in Europe and the USA—nor UDCA or other current therapies for PBC have a meaningfully beneficial effect on behavioural symptoms [100]. The gene discussed is PPARA; the disease is primary biliary cholangitis.